Wilate approved for bleeding episodes in von Willebrand disease (VWD) - MPR

Links shared publicly online about this topic.

1,545
total visits

Wilate approved for bleeding episodes in von Willebrand disease (VWD) - MPR

The FDA has approved wilate (double virus inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human], from Octapharma USA) for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

View full resource at empr.com

Tags: Bleeding, Incontinence, Disease and Condition, FDA, News, disease

Most Recently Shared on December 8, 2009 at 5:00 pm By:

MPR

MPR News: Wilate approved for bleeding episodes in von Willebrand disease (VWD): The FDA has approved wilate (doubl... http://bit.ly/7wpaRp

2 years ago...

Retweet

Favorite

Wilate available for bleeding episodes in von Willebrand disease (VWD) - ONA

oncologynurseadvisor.com — “Octapharma announced that wilate (double virus inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human]) is now available by prescription for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with mild or moderate forms of the illness in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.” View full resource at oncologynurseadvisor.com